Lilly looks to double Japan business by 2020
This article was originally published in Scrip
Lilly's global business might be facing challenges given the loss of exclusivity for the atypical antipsychotic Zyprexa (olanzapine) in most major markets, a major factor behind the US major's expectation of low single digit growth this year. But Japan remains one bright spot for the firm, which has had another strong sales increase in this key market and is aiming for a top 10 ranking there by the end of the decade.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.